List view / Grid view


Using bioactivity profiling to support the progression of phenotypic hits

7 September 2018 | By ,

This webinar, held on 28 June 2018, illustrated the optimisation of hits derived from a target-agnostic phenotypic screen, using a strategy based on combining bioactivity profiling and reference compound characterisation. Keynote speaker Arsenio Nueda, Head of Molecular Biology at Almirall, responded as follows to questions posed during the webinar.

The rise of high-throughput flow cytometry in drug discovery

7 September 2018 | By

Flow cytometry has played a key role in drug development, largely due to its ability to measure up to twenty parameters on single cells or particles suspended in a fluid stream. Typically, cells are labelled with fluorescent markers and passed through a series of lasers, after which the resultant fluorescent…

Antibodies In-Depth Focus 2018

6 September 2018 | By

In this In-Depth Focus, Stefan R. Schmidt discusses the current status and future perspectives of monoclonal antibodies and Tony Edge explains why the determination of aggregate is critical in the formation of monoclonal antibodies.

Expert view: Assays to measure the potency of therapeutic antibodies used in combination with other drugs for Immuno‑Oncology treatments

6 September 2018 | By

Growing evidence reveals that using single immunotherapies to treat oncological disorders may lead to cancer-killing T-cell overdrive,initiating life-threatening autoimmune reactions including cytokinestorm; also known as hypercytokinemia or Cytokine Release Syndrome(CRS). Recently, checkpoint blockade using anti-programmed cell death1 (anti-PD-1) inhibitors became a prevalent approach for stimulatinganti-tumour immune system.

Aggregate formation for monoclonal antibodies

5 September 2018 | By

Workflows are generated around the analysis of large protein-derived therapeutics. The use of different analytical techniques is necessary to support drug development and testing, and thus increase generation of these new therapies. One of the areas that is most critical to this process is the determination of aggregates.

Expert view: Managing the complexity of finding new targets and drugging the undruggable

5 September 2018 | By

Assessing targets that are unable – or rather, extremely difficult – to reach pharmacologically, has prevented researchers from achieving desired clinical successes, most notably in the realm of cancer research. However, many advances are being made to shedlight on these difficult yet desirable target areas.

Expert view: New developments in real‑time live‑cell analysis

5 September 2018 | By

Live-cell analysis is now a well-established method that is part of the everyday cell biologist’s armoury for understanding cell biology. For over a decade, the functionality, throughput, and ease of use offered by real-time live-cell analysis has provided a platform for accurate and reproducible cell biology analysis in multiple biomedical…

Human iPSC-derived functional cells are revolutionising phenotypic drug discovery and development

4 September 2018 | By , , ,

Effective drug discovery and development relies largely on the availability of predictive pre-clinical model systems; the absence of which has contributed to late-stage drug failures and high expenditures. New industry acceptance of human induced pluripotent stem cell (hiPSC)-derived cardiomyocyte assay systems for regulatory safety pharmacology is now resulting in broad…

Upstream cell culture processes for the production of therapeutic proteins

4 September 2018 | By

Drugs of biological origin form the backbone of the drug discovery pipelines for many major pharmaceutical companies. These biologic therapeutics can be defined as proteins derived from eukaryotic cell culture processes. The ability of eukaryotic cells to undertake complex post-translational modifications makes them ideal vehicles for manufacturing proteins emerging from…